Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
95,963,102
-
Total 13F shares
-
67,877,270
-
Share change
-
+450,744
-
Total reported value
-
$7,730,039,829
-
Put/Call ratio
-
38%
-
Price per share
-
$113.86
-
Number of holders
-
244
-
Value change
-
+$45,641,218
-
Number of buys
-
121
-
Number of sells
-
126
Institutional Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q1 2021
As of 31 Mar 2021,
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) was held by
244 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
67,877,270 shares.
The largest 10 holders included
PRICE T ROWE ASSOCIATES INC /MD/, Capital Research Global Investors, VANGUARD GROUP INC, BlackRock Inc., Capital International Investors, FEDERATED HERMES, INC., Capital World Investors, Clearbridge Investments, LLC, STATE STREET CORP, and ALKEON CAPITAL MANAGEMENT LLC.
This page lists
244
institutional shareholders reporting positions in this security
for the Q1 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.